◆英語タイトル:Generex Biotechnology Corp (GNBT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12409
◆発行会社(調査会社):
GlobalData
◆発行日:2018年12月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Generex Biotechnology Corp (Generex) carries out the research, development and commercialization of drug delivery systems and technologies. It developed a proprietary platform technology to deliver drugs into the human body through the oral cavity. The company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using its proprietary RapidMist device. Generex through its subsidiary, Antigen Express, has expanded its focus to include immunomedicines incorporating proprietary vaccine formulations for the treatment of infectious, malignant, allergic, and autoimmune diseases. Generex is headquartered in Miramar, Florida, the US.
Generex Biotechnology Corp (GNBT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Generex Biotechnology Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Generex Biotechnology Corp, Medical Devices Deals, 2012 to YTD 2018 9
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Antigen Express Enters into Agreement with Merck for KEYTRUDA 11
Generex Biotech Enters into Licensing Agreement with CannScience Innovations 12
Generex Biotech to Enter into Co-Development Agreement with NHTherapeutics 13
Licensing Agreements 14
Antigen Express Enters into Licensing Agreement with Shenzhen BioScien Pharma 14
Equity Offering 15
Generex Biotech Raises USD3 Million in First Tranche of Private Placement of Shares 15
Generex Biotechnology Raises USD0.8 Million in Private Placement of Series E 9% Convertible Preferred Stock and Warrants 17
Generex Biotech Completes Private Placement Of Units For US$2 Million 18
Acquisition 20
Generex Biotech to Acquire 51% Stake in Regentys 20
Generex Biotech to Acquire 51% Stake in Emmaus Life Sciences for USD225 Million 21
Generex Biotech to Acquire 51% Stake in Alfa Rhythm for USD5 Million 23
Generex Biotechnology Corp – Key Competitors 24
Generex Biotechnology Corp – Key Employees 25
Generex Biotechnology Corp – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Corporate Communications 27
Nov 15, 2018: Generex announces appointment of executive management team 27
Oct 12, 2018: Generex announces Anthony S. Crisci, Esq., CPA as general manager, chief compliance officer and corporate counsel of its new, wholly-owned subsidiary, NuGenerex distribution solutions 29
Jun 25, 2018: Generex Names Terry Thompson As Chief Operating Officer 30
Jan 25, 2017: Yutaka Niihara, MD, MPH, CEO of Emmaus Appointed Executive Chairman of Generex Biotechnology 31
Other Significant Developments 32
Jan 04, 2018: Generex CEO Provides 2017 Year-End Summary to Stakeholders 32
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35
List of Tables
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Generex Biotechnology Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Generex Biotechnology Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Generex Biotechnology Corp, Medical Devices Deals, 2012 to YTD 2018 9
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Antigen Express Enters into Agreement with Merck for KEYTRUDA 11
Generex Biotech Enters into Licensing Agreement with CannScience Innovations 12
Generex Biotech to Enter into Co-Development Agreement with NHTherapeutics 13
Antigen Express Enters into Licensing Agreement with Shenzhen BioScien Pharma 14
Generex Biotech Raises USD3 Million in First Tranche of Private Placement of Shares 15
Generex Biotechnology Raises USD0.8 Million in Private Placement of Series E 9% Convertible Preferred Stock and Warrants 17
Generex Biotech Completes Private Placement Of Units For US$2 Million 18
Generex Biotech to Acquire 51% Stake in Regentys 20
Generex Biotech to Acquire 51% Stake in Emmaus Life Sciences for USD225 Million 21
Generex Biotech to Acquire 51% Stake in Alfa Rhythm for USD5 Million 23
Generex Biotechnology Corp, Key Competitors 24
Generex Biotechnology Corp, Key Employees 25
Generex Biotechnology Corp, Subsidiaries 26
List of Figures
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Generex Biotechnology Corp, Medical Devices Deals, 2012 to YTD 2018 9